Tislelizumab in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma
Status:
Recruiting
Trial end date:
2022-10-31
Target enrollment:
Participant gender:
Summary
The primary objective of the study is to evaluate the efficacy of tislelizumab in
participants with relapsed/refractory classical Hodgkin lymphoma, as measured by the overall
response rate per the Lugano Classification, and as determined by the investigator.